- Home
- EWCZ vs IPHA Comparison
EWCZ vs IPHA Comparison
Compare EWCZ & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWCZ
- IPHA
- Stock Information
- Founded
- EWCZ 2004
- IPHA 1999
- Country
- EWCZ United States
- IPHA France
- Employees
- EWCZ N/A
- IPHA N/A
- Industry
- EWCZ Package Goods/Cosmetics
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- EWCZ Consumer Discretionary
- IPHA Health Care
- Exchange
- EWCZ Nasdaq
- IPHA Nasdaq
- Market Cap
- EWCZ 137.7M
- IPHA 160.1M
- IPO Year
- EWCZ 2021
- IPHA 2019
- Fundamental
- Price
- EWCZ $5.09
- IPHA $2.18
- Analyst Decision
- EWCZ Buy
- IPHA Strong Buy
- Analyst Count
- EWCZ 7
- IPHA 1
- Target Price
- EWCZ $5.86
- IPHA $11.00
- AVG Volume (30 Days)
- EWCZ 932.4K
- IPHA 28.8K
- Earning Date
- EWCZ 05-14-2025
- IPHA 03-27-2025
- Dividend Yield
- EWCZ N/A
- IPHA N/A
- EPS Growth
- EWCZ N/A
- IPHA N/A
- EPS
- EWCZ 0.21
- IPHA N/A
- Revenue
- EWCZ $216,469,000.00
- IPHA $20,831,349.00
- Revenue This Year
- EWCZ N/A
- IPHA $209.83
- Revenue Next Year
- EWCZ $2.39
- IPHA $83.15
- P/E Ratio
- EWCZ $24.77
- IPHA N/A
- Revenue Growth
- EWCZ N/A
- IPHA N/A
- 52 Week Low
- EWCZ $2.72
- IPHA $1.29
- 52 Week High
- EWCZ $12.04
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- EWCZ 60.83
- IPHA 53.46
- Support Level
- EWCZ $5.08
- IPHA $2.06
- Resistance Level
- EWCZ $5.60
- IPHA $2.24
- Average True Range (ATR)
- EWCZ 0.33
- IPHA 0.09
- MACD
- EWCZ 0.01
- IPHA -0.01
- Stochastic Oscillator
- EWCZ 65.79
- IPHA 53.33
About EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services and others.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.